去勢敏感性前立腺がん(CSPC)治療薬の世界市場:疫学予測

◆英語タイトル:Castrate-Sensitive Prostate Cancer (CSPC)- Epidemiology Forecast to 2030
◆商品コード:DELV20JU180
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2020年5月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後2営業日)
◆調査対象地域:アメリカ、ヨーロッパ、日本
◆販売価格オプション(消費税別)
Single User(180名様閲覧)USD3,750 ⇒換算¥393,750見積依頼/購入/質問フォーム
Three UserUSD5,625 ⇒換算¥590,625見積依頼/購入/質問フォーム
Site LicenseUSD7,500 ⇒換算¥787,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s ‘Castrate-Sensitive Prostate Cancer (CSPC)- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted CSPC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Geographies Covered
• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2017–2030

Castrate-Sensitive Prostate Cancer Understanding
Prostate cancer is a type of malignancy that occurs in the prostate gland. It is one of the most common types of cancer found in men. This cancer usually grows slowly and is confined to the prostate gland initially, where it may not cause serious harm.

According to the Cancer Treatment Centres of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells. The exact cause of prostate cancer is unknown. However, several things can increase the risk of developing this condition like age, family history, diet, high testosterone level, genome changes, and race.

In the majority of the cases, the symptoms of prostate cancer are not apparent in the early stages of the disease. The symptoms of prostate cancer may be different for each man, and other conditions may cause some of these symptoms like blood in semen, erectile dysfunction, painful ejaculation, pain in pelvic area, and numbness in legs.

Patients undergo regular prostate cancer screening before symptoms appear. Screening may involve one or more of the following tests: prostate-specific antigen (PSA), digital rectal exam (DRE), prostate ultrasound, prostate MRI, prostate Mp-MRI.

“Patients who have never received. i.e., are sensitive to ADT known as hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC). And, it was accessed that around 78% of biochemical recurrence/ progressive cases are non-metastatic CSPC/ HSPC.”

Epidemiology Perspective by DelveInsight
The CSPC epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The CSPC epidemiology data are studied through CSPC possible division to give a better understanding of the Disease scenario in the 7MM.

The disease epidemiology covered in the report provides historical as well as forecasted CSPC epidemiology [segmented as Total Prevalent Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer, Age-specific Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer by Clinical Stages, Total Non-metastatic and Metastatic Cases of CSPC, and Total Treated Cases of Non-metastatic and Metastatic CSPC] scenario of CSPC in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2017 to 2030.

Castrate-Sensitive Prostate Cancer Detailed Epidemiology Segmentation
• The total cases of CSPC in the 7MM were found to be 763,077 in 2017 which is expected to grow during the study period. In total cases of CSPC, nmCSPC/ nmHSPC cases estimated to be around 668,577 in 2017. On the other hand, mCSPC accounted for 94,500 cases in 2017 in the 7MM.

• Estimates show that the highest cases of CSPC were in the United States, followed by Germany, France, Japan, and Italy in 2017.

• In 2017, there were approximately 374,376 cases of CSPC in the United States.

• Japan accounted for approximately 9% of the total 7MM cases of CSPC.

Scope of the Report
• The CSPC report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

• The CSPC Report and Model provide an overview of the risk factors and global trends of CSPC in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)

• The report provides insight about the historical and forecasted patient pool of CSPC in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

• The report assesses the disease risk and burden and highlights the unmet needs of CSPC.

• The report provides the segmentation of the prostate cancer epidemiology by diagnosed prevalent cases in the 7MM.

• The report provides the segmentation of the prostate cancer epidemiology by Age-Specific cases in the 7MM.

• The report provides the segmentation of the prostate cancer epidemiology by Clinical Stages in the 7MM.

• The report provides the segmentation of the prostate cancer epidemiology by Non-Metastatic and Metastatic Cases of CSPC in the 7MM.

• The report provides the segmentation of the prostate cancer epidemiology by treated Non-Metastatic and Metastatic Cases of CSPC in the 7MM.

Report Highlights
• 11-Year Forecast of CSPC epidemiology

• 7MM Coverage

• Total Prevalent Cases of Prostate Cancer

• Diagnosed Prevalent cases segmentation: Age-Specific, Clinical-Stage, Patient Pool in mCSPC and nmCSPC

• Treated cases of mCSPC and nmCSPC

KOL-Views
We interview, KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the over CSPC scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to CSPC?

• What are the key findings pertaining to the CSPC epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?

• What would be the total number of patients of CSPC across the 7MM during the study period (2017–2030)?

• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?

• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?

• What are the various recent and upcoming events which are expected to improve the diagnosis of CSPC?

Reasons to buy
The CSPC Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global CSPC market

• Quantify patient populations in the global CSPC market to improve product design, pricing, and launch plans

• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CSPC therapeutics in each of the markets covered

• Understand the magnitude of CSPC population by its severity

• The CSPC epidemiology report and model were written and developed by Masters and PhD level epidemiologists

• The CSPC Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation

• Disease Risk and Burden

• Risk of disease by the segmentation

• Factors driving growth in a specific patient population

【レポートの目次】

1. Key Insights

2. Executive Summary of CSPC/HSPC

3. CSPC: Disease Background and Overview

3.1. Introduction

3.1.1. Signs and Symptoms of Prostate Cancer

3.1.2. Risk Factors and Causes of Prostate Cancer

3.1.3. Pathophysiology of Prostate Cancer

3.1.4. Prostate Neoplasia

3.1.5. Genetics of Prostate Cancer

4. Diagnosis of Prostate Cancer

4.1. Screening Tests for Prostate Cancer

4.2. Tests to Diagnose Prostate Cancer

4.3. Stages and Grades of Prostate Cancer

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Total Prevalent Cases of Prostate Cancer in the 7MM

5.3.2. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM

5.3.3. Total Non-metastatic and Metastatic Cases of CSPC in the 7MM

5.3.4. Total Treated cases of Non-metastatic CSPC Patients in the 7MM

5.3.5. Total Treated Cases of Metastatic CSPC Patients in the 7MM

5.4. The United States Epidemiology

5.4.1. Total Diagnosed Cases of Prostate Cancer in the United States

5.4.2. Age-specific Cases of Prostate Cancer in the United States

5.4.3. Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States

5.4.4. Total Non-metastatic and Metastatic Cases of CSPC in the United States

5.4.5. Total Treated cases of Non-metastatic CSPC Patients in the United States

5.4.6. Total Treated Cases of Metastatic CSPC Patients in the United States

6. EU-5 Country-wise Epidemiology

6.1. Germany

6.1.1. Total Diagnosed Prevalent cases of Prostate Cancer in Germany

6.1.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany

6.1.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany

6.1.4. Total Non-metastatic and Metastatic Cases of CSPC in Germany

6.1.5. Total Treated cases of Non-metastatic CSPC Patients in Germany

6.1.6. Total Treated Cases of Metastatic CSPC Patients in Germany

6.2. France

6.2.1. Total Diagnosed Prevalent cases of Prostate Cancer in France

6.2.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in France

6.2.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France

6.2.4. Total Non-metastatic and Metastatic Cases of CSPC in France

6.2.5. Total Treated cases of Non-metastatic CSPC Patients in France

6.2.6. Total Treated Cases of Metastatic CSPC Patients in France

6.3. Italy

6.3.1. Total Diagnosed Prevalent cases of Prostate Cancer in Italy

6.3.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy

6.3.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy

6.3.4. Total Non-metastatic and Metastatic Cases of CSPC in Italy

6.3.5. Total Treated cases of Non-metastatic CSPC Patients in Italy

6.3.6. Total Treated Cases of Metastatic CSPC Patients in Italy

6.4. Spain

6.4.1. Total Diagnosed Prevalent cases of Prostate Cancer in Spain

6.4.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain

6.4.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain

6.4.4. Total Non-metastatic and Metastatic Cases of CSPC in Spain

6.4.5. Total Treated cases of Non-metastatic CSPC Patients in Spain

6.4.6. Total Treated Cases of Metastatic CSPC Patients in Spain

6.5. United Kingdom

6.5.1. Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom

6.5.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom

6.5.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom

6.5.4. Total Non-metastatic and Metastatic Cases of CSPC in the United Kingdom

6.5.5. Total Treated cases of Non-metastatic CSPC Patients in the United Kingdom

6.5.6. Total Treated Cases of Metastatic CSPC Patients in the United Kingdom

6.6. Japan

6.6.1. Total Diagnosed Prevalent cases of Prostate Cancer in Japan

6.6.2. Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan

6.6.3. Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan

6.6.4. Total Non-metastatic and Metastatic Cases of CSPC in Japan

6.6.5. Total Treated cases of Non-metastatic CSPC Patients in Japan

6.6.6. Total Treated Cases of Metastatic CSPC Patients in Japan

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

Table 1 Summary of CSPC Epidemiology, and Key Events (2017–2030)

Table 2 Genetic Changes Associated with Prostate Cancer Tumorigenesis

Table 3 Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)

Table 4 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–2030)

Table 5 Total Non-metastatic Cases of CSPC/HSPC in the 7MM (2017–2030)

Table 6 Total Metastatic Cases of CSPC/HSPC in the 7MM (2017–2030)

Table 7 Total Treated Cases of nmHSPC/CSPC in the 7MM (2017–2030)

Table 8 Total Treated Cases of nmHSPC/CSPC in the 7MM (2017–2030)

Table 9 Total Treated Cases of mHSPC/CSPC in the 7MM (2017–2030)

Table 10 Total Treated Cases of mCSPC/HSPC in the 7MM (2017–2030)

Table 11 Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)

Table 12 Age-specific Cases of Prostate Cancer in the United States (2017–2030)

Table 13 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States (2017–2030)

Table 14 Total Non-metastatic Cases of CSPC/HSPC in the United States (2017–2030)

Table 15 Total Metastatic Cases of CSPC/HSPC in the United States (2017–2030)

Table 16 Total Treated Cases of nmHSPC/CSPC in the United States (2017–2030)

Table 17 Total Treated Cases of nmHSPC/CSPC in the United States (2017–2030)

Table 18 Total Treated Cases of mHSPC/CSPC in the United States (2017–2030)

Table 19 Total Treated Cases of mCSPC/HSPC in the United States (2017–2030)

Table 20 Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Table 21 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Table 22 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany (2017–2030)

Table 23 Total Non-metastatic Cases of CSPC/HSPC in Germany (2017–2030)

Table 24 Total Metastatic Cases of CSPC/HSPC in Germany (2017–2030)

Table 25 Total Treated Cases of nmHSPC/CSPC in Germany (2017–2030)

Table 26 Total Treated Cases of nmHSPC/CSPC in Germany (2017–2030)

Table 27 Total Treated Cases of mHSPC/CSPC in Germany (2017–2030)

Table 28 Total Treated Cases of mCSPC/HSPC in Germany (2017–2030)

Table 29 Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Table 30 Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Table 31 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France (2017–2030)

Table 32 Total Non-metastatic Cases of CSPC/HSPC in France (2017–2030)

Table 33 Total Metastatic Cases of CSPC/HSPC in France (2017–2030)

Table 34 Total Treated Cases of nmHSPC/CSPC in France (2017–2030)

Table 35 Total Treated Cases of nmHSPC/CSPC in France (2017–2030)

Table 36 Total Treated Cases of mHSPC/CSPC in France (2017–2030)

Table 37 Total Treated Cases of mCSPC/HSPC in France (2017–2030)

Table 38 Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Table 39 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Table 40 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (2017–2030)

Table 41 Total Non-metastatic Cases of CSPC/HSPC in Italy (2017–2030)

Table 42 Total Metastatic Cases of CSPC/HSPC in Italy (2017–2030)

Table 43 Total Treated Cases of nmHSPC/CSPC in Italy (2017–2030)

Table 44 Total Treated Cases of nmHSPC/CSPC in Italy (2017–2030)

Table 45 Total Treated Cases of mHSPC/CSPC in Italy (2017–2030)

Table 46 Total Treated Cases of mCSPC/HSPC in Italy (2017–2030)

Table 47 Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Table 48 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Table 49 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (2017–2030)

Table 50 Total Non-metastatic Cases of CSPC/HSPC in Spain (2017–2030)

Table 51 Total Metastatic Cases of CSPC/HSPC in Spain (2017–2030)

Table 52 Total Treated Cases of nmHSPC/CSPC in Spain (2017–2030)

Table 53 Total Treated Cases of nmHSPC/CSPC in Spain (2017–2030)

Table 54 Total Treated Cases of mHSPC/CSPC in Spain (2017–2030)

Table 55 Total Treated Cases of mCSPC/HSPC in Spain (2017–2030)

Table 56 Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Table 57 Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Table 58 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom (2017–2030)

Table 59 Total Non-metastatic Cases of CSPC/HSPC in the United Kingdom (2017–2030)

Table 60 Total Metastatic Cases of CSPC/HSPC in the United Kingdom (2017–2030)

Table 61 Total Treated Cases of nmHSPC/CSPC in the United Kingdom (2017–2030)

Table 62 Total Treated Cases of nmHSPC/CSPC in the United Kingdom (2017–2030)

Table 63 Total Treated Cases of mHSPC/CSPC in the United Kingdom (2017–2030)

Table 64 Total Treated Cases of mCSPC/HSPC in the United Kingdom (2017–2030)

Table 65 Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Table 66 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Table 67 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (2017–2030)

Table 68 Total Non-metastatic Cases of CSPC/HSPC in Japan (2017–2030)

Table 69 Total Metastatic Cases of CSPC/HSPC in Japan (2017–2030)

Table 70 Total Treated Cases of nmHSPC/CSPC in Japan (2017–2030)

Table 71 Total Treated Cases of nmHSPC/CSPC in Japan (2017–2030)

Table 72 Total Treated Cases of mHSPC/CSPC in Japan (2017–2030)

Table 73 Total Treated Cases of mCSPC/HSPC in Japan (2017–2030)

Figure 1 CSPC/HSPC SWOT Analysis

Figure 2 Prostate Cancer

Figure 3 Sign and Symptoms of Prostate Cancer

Figure 4 Risks Factors of Prostate Cancer

Figure 5 Pathophysiology of Prostate Cancer

Figure 6 Progression of Prostate Cancer and the Development of mCSPC/HSPC

Figure 7 Diagnosis of Prostate Cancer

Figure 8 Gleason Score of Prostate Cancer

Figure 9 Global Heat Map of Prostate Cancer

Figure 10 Total Prevalent Cases of Prostate Cancer in the 7MM (2017–2030)

Figure 11 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the 7MM (2017–2030)

Figure 12 Total Non-metastatic Cases of CSPC in the 7MM (2017–2030)

Figure 13 Total Metastatic Cases of CSPC in the 7MM (2017–2030)

Figure 14 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in the 7MM (2017–2030)

Figure 15 Total Treated Cases of mCSPC/HSPC by Line of Therapies in the 7MM (2017–2030)

Figure 16 Total Diagnosed Cases of Prostate Cancer in the United States (2017–2030)

Figure 17 Age-specific Cases of Prostate Cancer in the United States (2017–2030)

Figure 18 Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States (2017–2030)

Figure 19 Total Non-metastatic Cases of CSPC in the United States (2017–2030)

Figure 20 Total Metastatic Cases of CSPC in the United States (2017–2030)

Figure 21 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in the United States (2017–2030)

Figure 22 Total Treated Cases of mCSPC/HSPC by Line of Therapies in the United States (2017–2030)

Figure 23 Total Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Figure 24 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Germany (2017–2030)

Figure 25 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Germany (2017–2030)

Figure 26 Total Non-metastatic Cases of CSPC in Germany (2017–2030)

Figure 27 Total Metastatic Cases of CSPC in Germany 2017–2030)

Figure 28 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in Germany (2017–2030)

Figure 29 Total Treated Cases of mCSPC/HSPC by Line of Therapies in Germany (2017–2030)

Figure 30 Total Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Figure 31 Age-specific Diagnosed Prevalent cases of Prostate Cancer in France (2017–2030)

Figure 32 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in France (2017–2030)

Figure 33 Total Non-metastatic Cases of CSPC in France (2017–2030)

Figure 34 Total Metastatic Cases of CSPC in France2017–2030)

Figure 35 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in France (2017–2030)

Figure 36 Total Treated Cases of mCSPC/HSPC by Line of Therapies in France (2017–2030)

Figure 37 Total Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Figure 38 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Italy (2017–2030)

Figure 39 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Italy (2017–2030)

Figure 40 Total Non-metastatic Cases of CSPC in Italy (2017–2030)

Figure 41 Total Metastatic Cases of CSPC in Italy 2017–2030)

Figure 42 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in Italy (2017–2030)

Figure 43 Total Treated Cases of mCSPC/HSPC by Line of Therapies in Italy (2017–2030)

Figure 44 Total Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Figure 45 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Spain (2017–2030)

Figure 46 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Spain (2017–2030)

Figure 47 Total Non-metastatic Cases of CSPC in Spain (2017–2030)

Figure 48 Total Metastatic Cases of CSPC in Spain (2017–2030)

Figure 49 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in Spain (2017–2030)

Figure 50 Total Treated Cases of mCSPC/HSPC by Line of Therapies in Spain (2017–2030)

Figure 51 Total Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Figure 52 Age-specific Diagnosed Prevalent cases of Prostate Cancer in the United Kingdom (2017–2030)

Figure 53 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in the United Kingdom (2017–2030)

Figure 54 Total Non-metastatic Cases of CSPC in the United Kingdom (2017–2030)

Figure 55 Total Metastatic Cases of CSPC in the United Kingdom (2017–2030)

Figure 56 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in the United Kingdom (2017–2030)

Figure 57 Total Treated Cases of mCSPC/HSPC by Line of Therapies in the United Kingdom (2017–2030)

Figure 58 Total Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Figure 59 Age-specific Diagnosed Prevalent cases of Prostate Cancer in Japan (2017–2030)

Figure 60 Total Diagnosed Prevalent cases of Prostate Cancer by Clinical Stages in Japan (2017–2030)

Figure 61 Total Non-metastatic Cases of CSPC in Japan (2017–2030)

Figure 62 Total Metastatic Cases of CSPC in Japan (2017–2030)

Figure 63 Total Treated Cases of n mCSPC/HSPC by Line of Therapies in Japan (2017–2030)

Figure 64 Total Treated Cases of mCSPC/HSPC by Line of Therapies in Japan (2017–2030)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[去勢敏感性前立腺がん(CSPC)治療薬の世界市場:疫学予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆